RecruitingNot ApplicableNCT07445984

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

Sponsor

Azienda Ospedaliero-Universitaria di Parma

Enrollment

250 participants

Start Date

Jul 28, 2021

Study Type

INTERVENTIONAL

Conditions

Acute Leukemia Chronic Leukemia Lymphoproliferative Disorders Myeloproliferative Disorders Myelodysplastic Disorders

Summary

The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.

Eligibility

Min Age: 1 Year

Plain Language Summary

Simplified for easier understanding

This study is building a detailed genetic and molecular profile of blood cancers — including leukemia, lymphoma, and myeloma — to better understand how each patient's cancer behaves and how it responds (or doesn't respond) to treatment. This information could help develop more personalized therapies in the future. **You may be eligible if:** - You are older than 1 year and are a patient at the University Hospital of Parma - You have been previously diagnosed with a blood cancer (retrospective enrollment), OR - You are currently being evaluated for a suspected blood cancer that requires a bone marrow or blood sample for diagnosis (prospective enrollment) - You are able to provide written informed consent **You may NOT be eligible if:** - You are 1 year old or younger - You are unable to provide informed consent for any reason Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERGenetic, molecular and/or omics analyses

The focus of our scientific approach is based on genetic, molecular and/or omics analyses performed with new technologies (Nanostring, NGS, single cell technologies, radiomics)